Abstract
Abstract Not AvailableStudy supported by Allergan.
Highlights
The objective of this 12-month multicenter, phase 3 study was to evaluate the safety and efficacy of onabotulinumtoxinA versus placebo for treatment of moderate to severe FHL and glabellar lines (GL) (40 U total), or FHL and GL with simultaneous treatment of crow’s feet lines (CFL) (64 U total)
Additional studies further support the use of onabotulinumtoxinA for managing upper facial lines, consisting of FHL treatment with simultaneous treatment of GL and crow’s feet lines (CFL) (Figure 1)3,4
The ITT population comprised 787 subjects: 568 were included in the modified ITT (mITT) population and 787 were included in the safety population – The majority of subjects completed the 6-month double-blind period; most of the discontinuations were for subjects being lost to follow-up or for personal reasons
Summary
Recent data demonstrated the efficacy and safety of onabotulinumtoxinA for treatment of forehead lines (FHL) with 20 U to the frontalis muscle and 20 U to the glabellar complex. Resting eyebrow position results from a balance between eyebrow elevator muscles (primarily frontalis) and eyebrow depressor muscles, including the procerus and corrugator muscles, which make up the glabellar complex2 – Because of the muscular anatomy, concurrent treatment of glabellar lines (GL) is recommended when treating FHL to reduce the risk of eyebrow ptosis. Additional studies further support the use of onabotulinumtoxinA for managing upper facial lines, consisting of FHL treatment with simultaneous treatment of GL and crow’s feet lines (CFL) (Figure 1). The objective of this 12-month multicenter, phase 3 study was to evaluate the safety and efficacy of onabotulinumtoxinA versus placebo for treatment of moderate to severe FHL and GL (40 U total), or FHL and GL with simultaneous treatment of CFL (64 U total)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have